Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase II Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in Metastatic Treatment naïve Pancreas Adenocarcinoma

Summary

The purpose of this phase II study is to evaluate the safety and efficacy of CXCR4 antagonist (motixafortide), (cemiplimab), gemcitabine and nab-paclitaxel in patients with pancreatic adenocarcinoma.

General Information

NCT#: NCT04543071
Study ID: AAAS9513
Trial Phase: Phase II

Trial Sponsor: Regeneron Pharmaceuticals, Gulam Manji, BioLine Rx
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Cemiplimab, Motixafortide (BL-8040)

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search